UroGen Pharma (URGN) option IV into data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts URGN Hot Sheet
Join SI Premium – FREE
UroGen Pharma (NASDAQ: URGN) 30-day option implied volatility is at 227; compared to its 52-week range of 59 to 228 into reports 82.3% 12-month duration of response data from Phase 3 trial.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NOV Inc (NOV) spreader of November and February 16 calls
- Boston Beer Company (SAM) PT Raised to $200 at Morgan Stanley
- EQT Corp. (EQT) PT Lowered to $75 at UBS
Create E-mail Alert Related Categories
OptionsRelated Entities
Options, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
